Adverse reactions after taking larotinib/larlotinib

Larotrectinib/Larotrectinib is a treatment drug for solid tumors and is widely used in adult and pediatric patients. This drug is particularly suitable for patients who carry neurotrophic receptor tyrosine kinase (NTRK) gene fusions and no known acquired resistance mutations, or whose disease has severely deteriorated after tumor metastasis or surgical resection and other treatments cannot meet their needs.

During the clinical use of larotrectinib, a series of adverse reactions and matters requiring attention have been observed. Among them, the more common adverse reactions include fatigue, nausea, dizziness, vomiting, anemia, increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), cough, constipation and diarrhea. Most of these symptoms are mild and can usually be effectively managed by adjusting the dosage of the medication or temporarily discontinuing the medication and restarting treatment when the symptoms subside. For patients who experience serious adverse reactions, the drug may need to be permanently discontinued.

Of particular concern are larotrectinib's possible neurotoxicity, hepatotoxicity, and potential toxicity to the embryo and fetus. Once the patient shows signs of these adverse reactions, the medication should be stopped immediately, and after the symptoms improve, a decision should be made on a case-by-case basis whether to resume treatment. In addition, clinical studies have also recorded some serious adverse reactions, such as fever, diarrhea, sepsis, abdominal pain, dehydration, cellulitis with vomiting, etc. When faced with these serious situations, doctors need to monitor patients closely and take timely and effective treatment measures.

In summary, larotrectinib has shown therapeutic effects in the treatment of solid tumors, but patients should fully understand possible adverse reactions during medication and adjust the treatment plan in a timely manner to ensure the safety and effectiveness of medication.